T cell reactivity to Bordetella pertussis is highly diverse regardless of childhood vaccination.

[1]  J. V. van Dongen,et al.  Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge , 2023, The Journal of clinical investigation.

[2]  Christine J. Boinett,et al.  "Antigen Discovery for Next-Generation Pertussis Vaccines using Immunoproteomics and Transposon Directed Insertion Sequencing". , 2022, The Journal of infectious diseases.

[3]  M. Huynen,et al.  Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination , 2022, Nature Communications.

[4]  G. Blanchard-Rohner.  Novel approaches to reactivate pertussis immunity , 2022, Expert review of vaccines.

[5]  Mat Makowski,et al.  Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults. , 2022, Vaccine.

[6]  J. McLellan,et al.  Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis , 2022, mBio.

[7]  A. Sette,et al.  Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period , 2022, bioRxiv.

[8]  L. Beckers,et al.  Reduced Bordetella pertussis-specific CD4+ T-Cell Responses at Older Age , 2022, Frontiers in Aging.

[9]  S. Mallal,et al.  SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron , 2022, Cell.

[10]  B. Kampmann,et al.  Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines , 2021, Vaccines.

[11]  B. Kuehn.  Resurgence of Pertussis Linked With Switch to Acellular Vaccine. , 2021, JAMA.

[12]  S. Tiwari,et al.  Comparative genomics of Bordetella pertussis and prediction of new vaccines and drug targets , 2021, Journal of biomolecular structure & dynamics.

[13]  D. Macina,et al.  Pertussis in Individuals with Co-morbidities: A Systematic Review , 2021, Infectious Diseases and Therapy.

[14]  Piyali Mukherjee,et al.  Seroprevalence of Bordetella pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort , 2021, COPD.

[15]  R. Scheuermann,et al.  A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy , 2021, JCI insight.

[16]  H. Hutton,et al.  An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers. , 2021, Vaccine.

[17]  K. Mills,et al.  Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract , 2020, Vaccines.

[18]  Bjoern Peters,et al.  Lack of evidence supporting a role of IFN-β and TGF-β in differential polarization of Bordetella pertussis specific-T cell responses. , 2020, Cytokine.

[19]  J. McLaren,et al.  T Cell Immunity to Bacterial Pathogens: Mechanisms of Immune Control and Bacterial Evasion , 2020, International journal of molecular sciences.

[20]  F. Mooi,et al.  Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site , 2020, PloS one.

[21]  P. Rohani,et al.  Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases , 2020, The Journal of Immunology.

[22]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[23]  Sandeep Kumar Dhanda,et al.  Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy , 2020, Journal of immunology research.

[24]  F. Mascart,et al.  Human Immune Responses to Pertussis Vaccines. , 2019, Advances in experimental medicine and biology.

[25]  P. Paterson,et al.  Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines , 2019, Front. Immunol..

[26]  A. King,et al.  Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. , 2019, JAMA pediatrics.

[27]  Morten Nielsen,et al.  IEDB-AR: immune epitope database—analysis resource in 2019 , 2019, Nucleic Acids Res..

[28]  T. Merkel,et al.  Pertussis vaccines and protective immunity. , 2019, Current opinion in immunology.

[29]  C. Locht,et al.  PERISCOPE: road towards effective control of pertussis. , 2019, The Lancet. Infectious diseases.

[30]  N. Demarteau,et al.  The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review , 2019, Expert review of vaccines.

[31]  C. Locht,et al.  The Role of Mucosal Immunity in Pertussis , 2019, Front. Immunol..

[32]  K. Mills,et al.  Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis , 2019, Emerging microbes & infections.

[33]  Sandeep Kumar Dhanda,et al.  A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussis , 2018, Front. Immunol..

[34]  S. Plotkin.  Composition of pertussis vaccine given to infants determines long-term T cell polarization , 2018, The Journal of clinical investigation.

[35]  Bjoern Peters,et al.  Development of a novel clustering tool for linear peptide sequences , 2018, Immunology.

[36]  B. Pulendran,et al.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters , 2018, The Journal of clinical investigation.

[37]  Jianhong Wu,et al.  Acellular pertussis vaccines effectiveness over time: A systematic review, meta-analysis and modeling study , 2018, PloS one.

[38]  E. Sanders,et al.  Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles , 2018, Front. Immunol..

[39]  J. Wade,et al.  The BvgAS Regulon of Bordetella pertussis , 2017, mBio.

[40]  K. Edwards,et al.  What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing. , 2017, Cold Spring Harbor perspectives in biology.

[41]  Zhiyun Chen,et al.  Immune persistence after pertussis vaccination , 2017, Human vaccines & immunotherapeutics.

[42]  S. Mallal,et al.  Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses , 2017, PloS one.

[43]  J. Greenbaum,et al.  T-cell epitope conservation across allergen species is a major determinant of immunogenicity. , 2016, The Journal of allergy and clinical immunology.

[44]  Alessandro Sette,et al.  A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood , 2016, The Journal of Immunology.

[45]  Bjoern Peters,et al.  Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. , 2016, Cellular immunology.

[46]  C. Rizzo,et al.  Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013). , 2016, Journal of medical microbiology.

[47]  E. Dudley,et al.  Diversity of secretion systems associated with virulence characteristics of the classical bordetellae. , 2015, Microbiology.

[48]  G. Fedele,et al.  T-cell immune responses to Bordetella pertussis infection and vaccination. , 2015, Pathogens and disease.

[49]  M. Mokhtari,et al.  Does working in hospital increases seroprevalence and carrier state against Bordetella pertussis? , 2015, Advanced biomedical research.

[50]  J. Pennings,et al.  Immunoproteomic Profiling of Bordetella pertussis Outer Membrane Vesicle Vaccine Reveals Broad and Balanced Humoral Immunogenicity. , 2015, Journal of proteome research.

[51]  John Sidney,et al.  Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes , 2014, BCB.

[52]  N. Klein.  Licensed pertussis vaccines in the United States , 2014, Human vaccines & immunotherapeutics.

[53]  B. Kan,et al.  Prevalence of asymptomatic Bordetella pertussis and Bordetella parapertussis infections among school children in China as determined by pooled real-time PCR: A cross-sectional study , 2014, Scandinavian journal of infectious diseases.

[54]  T. Merkel,et al.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model , 2013, Proceedings of the National Academy of Sciences.

[55]  A. Rowhani-Rahbar,et al.  Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers , 2013, Pediatrics.

[56]  K. Mills,et al.  Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.

[57]  Bjoern Peters,et al.  Memory T Cells in Latent Mycobacterium tuberculosis Infection Are Directed against Three Antigenic Islands and Largely Contained in a CXCR3+CCR6+ Th1 Subset , 2013, PLoS pathogens.

[58]  K. Mills,et al.  Immunity to the respiratory pathogen Bordetella pertussis , 2012, Mucosal Immunology.

[59]  K. Krogfelt,et al.  Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. , 2010, Journal of medical microbiology.

[60]  Ravi V. Kolla,et al.  Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen , 2010, The Journal of Immunology.

[61]  P. Rohani,et al.  Estimating the Duration of Pertussis Immunity Using Epidemiological Signatures , 2009, PLoS pathogens.

[62]  Magdalini Moutaftsi,et al.  Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. , 2008, Immunity.

[63]  R. Tsolis,et al.  Inactivation of the Type IV Secretion System Reduces the Th1 Polarization of the Immune Response to Brucella abortus Infection , 2008, Infection and Immunity.

[64]  Wei Li,et al.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines , 2007, BMC Bioinformatics.

[65]  J. Tropea,et al.  Human cytolytic T cell recognition of Yersinia pestis virulence proteins that target innate immune responses. , 2006, The Journal of infectious diseases.

[66]  Mirjam Kretzschmar,et al.  The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. , 2006, The Journal of infection.

[67]  Kelly D Elder,et al.  Strain-Dependent Role of BrkA during Bordetella pertussis Infection of the Murine Respiratory Tract , 2004, Infection and Immunity.

[68]  D. Greenberg,et al.  Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. , 2004, The Journal of infectious diseases.

[69]  J. Cherry,et al.  A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. , 2004, Pediatrics.

[70]  J. Cherry,et al.  Serologic response and antibody-titer decay in adults with pertussis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  J. Cherry,et al.  Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  H. Schmitt,et al.  Pertussis in adults: frequency of transmission after household exposure , 1995, The Lancet.

[73]  D. Jenkinson.  Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study , 1988, British medical journal.

[74]  E. Hewlett,et al.  Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. , 1991, The Journal of infectious diseases.